Library

Bevacizumab in the treatment of ovarian cancer : Summary [printed text] / Mattias Neyt , Author ; Stephan Devriese , Author ; Cécile Camberlin , Author ; Joan Vlayen , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2017 . - 15 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 285Cs) .
ISSN : D/2017/10.273/23 : € 0,00
Study 2015-06
Languages : English (eng)

Descriptors:	Classification WP 322 Neoplasms Indexation 2015-06 ; Angiogenesis Inhibitors ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; R285
Contents note:	FOREWORD 1 -- SUMMARY 2 -- 1. INTRODUCTION 3 -- 2. METHODS 4 -- 2.1. CLINICAL EFFECTIVENESS AND SAFETY 4 -- 2.2. COST-EFFECTIVENESS 4 -- 2.2.1. Literature review 4 -- 2.2.2. Economic model 4 -- 3. CLINICAL EFFICACY AND SAFETY OF BEVACIZUMAB 5 -- 3.1. UNPROVEN EFFECT OF FIRST-LINE BEVACIZUMAB ON OVERALL SURVIVAL AND QUALITY OF LIFE, BUT SUBGROUPS MAY BENEFIT 5 -- 3.2. POSITIVE EFFECT OF SECOND-LINE BEVACIZUMAB ON PROGRESSION-FREE SURVIVAL -- AND ONE SPECIFIC ITEM OF QUALITY OF LIFE, BUT NOT ON OVERALL SURVIVAL 6 -- 3.3. ACCEPTABLE SIDE EFFECTS 7 -- 3.4. QUALITY OF LIFE AND OVERALL SURVIVAL VERSUS PROGRESSION-FREE SURVIVAL? 7 -- 3.5. COMPARISON OF THE CLINICAL EVIDENCE WITH THE CURRENT REIMBURSEMENT CRITERIA 8 -- 4. COST-EFFECTIVENESS 12 -- 4.1. IS BEVACIZUMAB COST-EFFECTIVE IN A BELGIAN CONTEXT? 12 -- 4.2. WHAT DO OTHER ECONOMIC EVALUATIONS SAY? 12 -- 4.3. OVERALL QUALITY OF LIFE 13 -- 4.4. ECONOMIC EVALUATIONS AS PART OF THE REIMBURSEMENT REQUEST 13 -- 4.5. FOCUS ON STAGE IV SUBGROUP IN FIRST LINE 13 -- 4.6. CONFIDENTIAL CONTRACTS AND CHANGING REIMBURSEMENT CONDITIONS 14 -- RECOMMENDATIONS 15
Link for e-copy:	https://doi.org/10.57598/R285CS
Format of e-copy:	PDF (355 Kb)
Record link:	https://kce.docressources.info/index.php?lvl=notice_display&id=4168